UNLIMITED

STAT

Opinion: Digital health startups may not want to do randomized trials, but they need to

Digital health is a fast-moving field that's impeded by the slow timelines of clinical research organizations and top medical journals. They need to pick up the pace.

The general theme of digital health care is easy to grasp — maybe too easy. Somewhere, right now, a hopeful CEO is making a pitch to a potential investor about how its new digital product or service will transform health care and improve outcomes, reduce costs, and save time.

The story works. Digital health care startups are attracting billions of dollars in risk capital, with aggregate investments reaching $7 billion so far in 2018, all in the hopes of modernizing our broken health care system.

While the story is easy to tell, proving it poses a far greater challenge.

As the CEO of a company that, partnered with to conduct the first large, prospective, randomized controlled trial using our FDA-cleared Virtual Exercise Rehabilitation Assistant (VERA) with traditional physical therapy.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min readAmerican Government
Opinion: STAT+: Pharmacy Benefits Managers Should Be Worried
Former FTC policy director David Balto says PBMs should be very worried about the new Trump administration and pending congressional action.
STAT1 min read
STAT+: For A Leukemia That Keeps Returning, AbbVie Drug May Offer Chance For A Deep Remission
Most patients with chronic lymphocytic leukemia eventually relapse. A bispecific antibody drug may give them "another can to kick."
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Novo Holdings Proceeding With Catalent Deal, Sanofi Threatened With Sanctions, And More
Novo Holdings can proceed with its planned $16.5 billion acquisition of Catalent after U.S. regulators declined to challenge the deal

Related Books & Audiobooks